Before novel systemic treatments significantly improved outcomes in metastatic melanoma, a study of 912 patients diagnosed with cutaneous melanoma analyzed the relationships between NRAS and BRAF mutations, tumor characteristics, and survival. This evidence concerns the gene BRAF and neoplasm.